As the pace of drug development accelerates, choosing the right early-phase partner is more critical than ever. Lonza is investing in the future of early development through a significant expansion at our Visp site, purpose-built to support fast, flexible, and integrated early-phase programs.
In this presentation, we’ll showcase how our latest offerings—from SFS and AI-enabled route scouting to PBBM modeling, high-throughput experimentation, and our new Lonza Design2Optimize® platform—work in synergy to streamline decision-making, reduce risk, and accelerate timelines. A key enabler of this innovation is the integration of robotic manufacturing and automated high-throughput experimentation, which together deliver scalable, data-rich workflows that enhance predictability and speed. Learn how Lonza’s integrated services support more robust candidate progression from preclinical through Phase I and beyond. Discover why global innovators are choosing Lonza not just for scale, but for smart, strategic collaboration at the earliest and most critical stages of development.
